Physician profile
Scott Eugene Catone
NPI 1417175498
$7,527.21
in general payments reported to CMS, 2019-2025
22 companies · $1,990 in 2025
The $1,990 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,539 · 2022: $910 · 2023: $1,366 · 2024: $1,722 · 2025: $1,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,077.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,155.54 | 2021-2025 | Wavewriter Alpha Prime 16, Infinion 16, Avista Mri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,194.24 | 2021-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $703.14 | 2021-2025 | Xtampza, Belbuca |
| Nevro Corp. | $530.47 | 2021-2022 | |
| Abbott Laboratories | $512.43 | 2021-2025 | Proclaim |
| Abbvie INC. | $395.02 | 2021-2025 | |
| Vertos Medical, INC. | $206.12 | 2021-2024 | Mild Device Kit |
| Scilex Pharmaceuticals INC. | $154.76 | 2022-2024 | Ztlido |
| Vertex Pharmaceuticals Incorporated | $116.67 | 2024-2025 | |
| Nalu Medical, INC. | $98.32 | 2021-2024 | Nalu Neurostimulation System |
| Pfizer INC. | $95.85 | 2023-2025 | |
| Medtronic, INC. | $79.54 | 2023-2025 | Intellis Adaptivestim |
| Merz Pharmaceuticals, LLC | $60.69 | 2023 | Xeomin |
| Relievant Medsystems, INC. | $38.38 | 2021-2022 | |
| Curonix LLC | $36.59 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $28.87 | 2024 | Exparel, Iovera |
| Painteq LLC | $25.95 | 2021 | |
| Virtus Pharmaceuticals LLC | $22.86 | 2025 | Levorphanol Tartrate |
| Forte Bio-Pharma LLC | $21.50 | 2024 | Prolate, Nalocet |
| Arbor Pharmaceuticals, INC. | $18.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.05 | 2023 | Seglentis |
| Si-Bone, INC. | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Catone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.